home All News open_in_new Full Article

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States  Business Wire


today 12 h. ago attach_file Politics

attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics


ID: 2861530063
Add Watch Country

arrow_drop_down